Where Operational Experience Meets Investor Acumen
After nearly a decade as a Director at PAREXEL managing global clinical trial portfolios valued up to $500M, our founder recognized a critical gap in biotech investing: the most promising science is consistently put at risk by avoidable operational failures.
HYGEIA was founded not just to advise, but to provide investors with the specialized, on-the-ground operational intelligence needed to identify and mitigate these risks before they destroy capital. We have been in the trenches of complex global trials and know precisely what separates a successful clinical program from a costly write-down. Our singular focus is to bring that director-level CRO insight directly to your diligence process and portfolio management.
Why Investors Choose HYGEIA
1. Director-Level Insight, Not Analyst-Level Reports You work directly with a former CRO director, not a junior consultant. We provide decisive judgment and a clear, actionable roadmap based on decades of experience, not just a summary of data. We’ve managed the budgets, negotiated the vendor contracts, and rescued the failing trials you’re seeking to avoid.
2. Speed and Focus Built for Deal Flow Our “sprint” model is designed to match the velocity of your investment cycle. We deliver comprehensive, high-impact diligence reports in weeks, not months, providing the clear “Go/No-Go” signals needed to make timely and confident capital allocation decisions.
3. Unconflicted, Capital-Focused Advice As a truly independent advisor, our only goal is to protect your capital and maximize your asset’s potential. We don’t sell software, and we aren’t conflicted by downstream service offerings. Our value is measured by the quality and accuracy of our analysis and our ability to help you secure a successful exit.
